ClinicalTrials.gg
CompletedNCT01176903GLY2Updated Oct 29, 2021

Safety and Efficacy Study of Glyco pMDI After Single and Repeated Administration

A Phase 1/2 interventional study of Glycopyrrolate and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 1 site in United Kingdom. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
49th of 73
65 · median 152
Started
2010
with 4 others
Phase 1/2
2 of 73
none open now
Registered
14th of 73
by date
Lead sponsor
13 of 73
Chiesi Farmaceutici S.p.A.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 49th largest by enrollment, is one of 5 that started in 2010, is one of 2 in phase 1/2, and was the 14th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and the efficacy of Glycopyrrolate as pMDI after single and repeated administration.

Read the detailed description

The study is divided into two parts:

  • Part 1 will be conducted according to a single-centre, randomized, double-blind, placebo-controlled, single-dose escalation, alternating crossover design in two groups of COPD patients.

Treatments to be administered on Part 1 (SD1, SD2, SD3, SD4, SD5, SP). The primary objective of Part 1 is the evaluation of the safety and tolerability of Glyco after single administration.

  • Part 2 will be conducted according to a single-centre, randomized, double-blind, placebo-controlled, 4-period, 4-treatment, repeated dose cross-over design followed by an open-label extension period with tiotropium.

Treatments administered on Part 2 (MD1, MD2, MD3, MP, Tiotropium). On the last treatment day in the morning, Formoterol 12 µg will be administered to all patients on top of placebo or Glyco or Tiotropium.

The primary objective of Part 2 is the evaluation of the efficacy of Glyco after repeated administration.

Part 2 will start after a safety review of the results obtained from Part 1.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females patients aged 40-75 years;
  • Written obtained;
  • Diagnosis of moderate-severe , according to the GOLD guidelines;
  • Current or ex-smokers with a smoking history of ≥ 10 pack-years
  • Post bronchodilator between 40% and 80% predicted values (40% ≤ FEV1 \< 80%), documented at screening visit ;
  • Post bronchodilator FEV1/Forced Vital Capacity (FEV1/FVC) ≤ 0.70 (absolute value) documented at screening visit;
  • Airway reversibility of at least 100 mL within 30 to 45 minutes after inhalation of ipratropium 80µg.

Exclusion criteria

Exclusion Criteria:

  • History of chronic or seasonal allergy
  • Blood eosinophil count above 600 per µl
  • findings on physical examination laboratory and parameters at screening
  • Occurrence of clinically relevant abnormalities in the 24-h Holter ECG recording at screening;
  • Significant disease not related to (eg. Myocardial infarction, stroke within the preceding 6 months);
  • Respiratory tract infection (including upper tract) 4 weeks prior to study entry requiring changing treatment;
  • Patients requiring oxygen therapy on a daily basis for chronic hypoxemia;
  • History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency, or any other significant lung disease which is considered to be clinically significant by the investigator.
  • Intolerance/ or any to treatment with M3 Antagonist or any of the contained in the formulations used in the study.
  • History of alcohol or substance abuse that in the opinion of the Investigator may be of clinical significance.
  • Patients treated with slow-release oral or parental 8 weeks prior to Screening Visit.
  • Patients treated with tiotropium in the 10 days prior to the Screening Visit;
  • Pregnant or lactating women and female or male subjects not willing to use an acceptable method of .
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Glyco SD1

    Single administration of Glyco pMDI dose level 1

    Drug: Glycopyrrolate

  • Experimental
    Glyco SD2

    Single administration of Glyco pMDI dose level 2

    Drug: Glycopyrrolate

  • Experimental
    Glyco SD3

    Single administration of Glyco pMDI dose level 3

    Drug: Glycopyrrolate

  • Experimental
    Glyco SD4

    Single administration of Glyco pMDI dose level 4

    Drug: Glycopyrrolate

  • Experimental
    Glyco SD5

    Single administration of Glyco pMDI dose level 5

    Drug: Glycopyrrolate

  • Placebo comparator
    Placebo SP

    Single administration of Placebo pMDI

    Drug: placebo

  • Experimental
    Glyco MD1

    Multiple administration of Glyco pMDI dose level 1

    Drug: Glycopyrrolate

  • Experimental
    Glyco MD2

    Multiple administration of Glyco pMDI dose level 2

    Drug: Glycopyrrolate

  • Experimental
    Glyco MD3

    Multiple administration of Glyco pMDI dose level 3

    Drug: Glycopyrrolate

  • Placebo comparator
    Placebo MP

    Multiple administration of placebo pMDI

    Drug: placebo

  • Active comparator
    Tiotropium

    Multiple administration of tiotropium

    Drug: Tiotropium

Interventions

  • pressurized metered dose inhaler

    Also known as: CHF 5259

  • inhalation powder, hard capsule

    Also known as: Spiriva

  • Drugplacebo

    pressurized metered dose inhaler

06

What researchers measure

Primary outcomes

  1. Safety

    Adverse events, vital signs, ECG parameters, 24-hours ECG holter recording, clinical laboratory abnormalities. This primary outcome is for the Part 1 of the study.

    Time frame: Up to 24 hours after single administration

  2. Lung function (trough FEV1)

    This primary variable is for the Part 2 of the study.

    Time frame: 12 hours post dose after repeated administration

Secondary outcomes

  1. Lung function

    for Part 1 of the study

    Time frame: up to 24 hours post dose

  2. Lung function (other parameters)

    for Part 2 of the study

    Time frame: up to 12 hours after repated administration

  3. Body plethysmography

    for Part 2 of the study

    Time frame: up tp 12 hours after repeated administration

  4. Pharmacokinetics

    Pharmacokinetics in plasma and urine. For Part 2 of the study.

    Time frame: up to 12 hours after single and repeated administration

  5. Safety

    Adverse events, Vital signs, ECG parameters, 24-hour ECG holter recording. For Part 2 of the study.

    Time frame: up to 12 hours after single and repeated administration

07

Study locations

1 site
  • Medicines Evaluation Unit
    Manchester, M23 9QZ, United Kingdom
08

References and documents

Publications

  • Singh D, Scuri M, Collarini S, Vezzoli S, Mariotti F, Muraro A, Acerbi D. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study. Int J Chron Obstruct Pulmon Dis. 2017 Jul 7;12:2001-2014. doi: 10.2147/COPD.S137659. eCollection 2017. PubMed 28744115 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2010
First posted
Aug 6, 2010
Start
Aug 2010
Primary completionActual
Nov 2010
CompletionActual
Aug 2011
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01176903
Responsible party
Sponsor
First posted
Aug 6, 2010
Start date
Aug 2010
Primary completion
Nov 2010
Completion
Aug 2011
Last update
Oct 29, 2021

Study contacts

Dave Singh, MD
principal investigator · Medicines Evaluation Unit Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion